Appendix 4D - Condensed Financial Report
28 Febuary 2008

African Rainbow Minerals Limited (ARM), Anvil Mining Limited, Assmang Limited and Paladin Energy Limited Join Donor Syndicate for the Virax Southern Africa HIV Therapeutic Vaccine Project
27 Febuary 2008

Convertible Note Issue Raises $1.88 million
18 Febuary 2008

VIR201 Phase IIA Trial Results Now Published in Peer Reviewed Scientific Journal – Human Vaccines
6 Febuary 2008

Chairman’s Letter describing Fund Raising and the Corporate Strategy
30 January 2008

Technology License with Transgene: Product TG4010 Interim Results
24 January 2008

Appendix 3X & Appendix 3Z
22 January 2008

Convertible Note Issue - Amended Closing Date and Despatch Date
21 January 2008

Board Changes Completed and Extension of Rights Issue Closing Date
17 January 2008

Rights Issue Minimum Subscription Achieved
7 January 2008

Prospectus & Appointment of CEO
19 December 2007

Appendix 3B
19 December 2007

AGM Results
27 November 2007

Virax Fund Raising Proposed
27 November 2007

AGM Results and CEO Presentation
27 November 2007

Notice of General Annual Meeting
26 October 2007

Annual Report
21 September 2007

Changes to Distribution of Annual Reports
20 September 2007

Virax Announces Grant of Key VIR201 Patent in Europe
19 September 2007

Appendix 4E - Preliminary Final Report
30 August 2007

Virax Confirms Receipt of A$1m in Milestone Payments from Transgene
23 August 2007

Publication of VIR201 Phase Iia Trial Results in Peer Reviewed Scientific Journal
18 July 2007

Virax Announces Allowance of Key VIR201 Patent in the United States
10 July 2007

Virax to Receive Milestone Payment from Transgene through Co-X-Gene™ Technology Licence
7 June 2007

Appendix 3B
25 May 2007

Market Update
18 May 2007

Virax to Receive Milestone Payment from Transgene through Co-X-Gene™ Technology Licence
12 April 2007

Appendix 3Y
14 March 2007

Virax Grants Transgene Co-X-Gene™ Technology License for Two Immunotherapeutic Products
13 March 2007

Half Yearly Report
28 February 2007

AGM Results & CEO Presentation Pdf (1.4 Mb)
27 November 2006

Mining Majors Join Forces to Sponsor Virax HIV Drug Clinical Trial in South Africa
27 November 2006

Chairman’s AGM Address
27 November 2006

Virax gets green light for commencement of Phase II US clinical trials of VIR201
17 November 2006

Virax Rights Issue Raises $2.36 million to Date
09 November 2006

Appendix 3B
09 November 2006

Funding Secured for Southern Africa HIV VIR201 Trial
26 October 2006

Clinical Trial Application Lodged with US Food and Drug Administration and Extension of Rights Issue Closing Date
17 October 2006

Milestone Update
09 October 2006

Appendix 3B
22 September 2006

$4.1 million Pro-Rata Rights Issue
22 September 2006

Annual Report
19 September 2006

Virax lodges application to conduct a HIV clinical trial in South Africa
04 September 2006

Full Year Report and Milestone Update
17 August 2006

Appendix 3B
11 May 2006

Appendix 3Y
10 May 2006

Appendix 3Y
3 May 2006

Appendix 3B
28 April 2006

Appendix 3Y
13 April 2006

Virax Shareholder Letter
26 March 2006

Half Yearly Report and Milestone Update
16 March 2006

Virax Rights Issues Closed Raising $3.7million
23 February 2006

Additional $600,000 Brings Issue Raising to $3.7 million
31 January 2006

Appendix 3Y
25 January 2006

Pro Rata Share Issue Raises $3.1 million
20 January 2006

Capital Raising Passes 50% Subscription
12 January 2006

Virax Exceeds Minimum Subscription for Rights Offer
10 January 2006

Virax Receives Independent Research Report
21 December 2005

Independent Analyst Report
21 December 2005

Appendix 3b - Replacement of Appendix 3B lodged on 21st and 25th November 2005
15 December 2005

VHL Options Expiry Notice
15 December 2005

Response to ASX Query
13 December 2005

Extension of Rights Issue Closing Date
9 December 2005

Non Renounceable Pro Rata Issue - Prospectus
25 November 2005

Appendix 3b - Amendment of Appendix 3B lodged on 21 November 2005
New issue announcement,application for quotation of additional securities and agreement
25 November 2005

Non Renounceable Rights Issue
21 November 2005

Virax Holdings Limited Makes $250,000 in Share Placement
21 November 2005

AGM Results & CEO Presentation PDF (350k)
21 November 2005

Chairmans Address at AGM
21 November 2005

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
21 November 2005

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
18 November 2005

Development of VIR201 remains top priority for Virax
25 October 2005

Annual Report
30 September 2005

Appendix 4E - Preliminary Final Report
15 September 2005

Virax Review - July 2005
26 July 2005

Virax Initiatives in South Africa
13 May 2005

Virax Advances HIV/AIDS Co-X-Gene™ Programs on Two Fronts
15 April 2005

Half Yearly Report Period Ended 31 December 2004
28 February 2005

Appendix 4D - Half Yearly Reprt to 31 December 2004
28 February 2005

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
17 January 2005

Virax's Share Purchase Plan raised $3.25 million
13 January 2005

Promising Preclinical Results For Prostate Cancer Treatment
22 December 2004

Share Purchase Plan - December 2004
13 December 2004

Share Purchase Plan
Variation of the minimum subscription to $1,000 and Extension of Closing date to 30 December 2004
8 December 2004

Share Purchase Plan
25 November 2004

Proposed issue of securities under a Share Purchase Plan (SPP)
25 November 2004

Share Purchase Plan
25 November 2004

AGM Results 2004
9 November 2004

Virax Report to Shareholders 2004
19 October 2004

Notice of Annual General Meeting 2004
10 October 2004

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
1 October 2004

Appendix 4e - Preliminary Final Report
31 August 2004

Virax Update
29 July 2004

New Appointment To The Board Of Virax Holdings Limited
26 May 2004

Virax Progresses Its HIV Drug
18 May 2004

Virax Invited To Join Innovation Xchange Program
11 May 2004

Prostate Cancer Preclinical Trials Commence
27 April 2004

Notice of Change of Interests of Substantial Holding
30 March 2004

Notice of Initial Substantial Holding
29 March 2004

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
26 March 2004

ASIC Class Order 02/1180
26 March 2004

Placement Raises $3.7 million
22 March 2004

Notice of Initial Substantial Holding
16 March 2004

Virax Review Volume 6, Issue 1 - March 2004
2 March 2004

Virax technology produces positive clinical results in French cancer trials
2 March 2004

NCHECR Presentation of VIR201 Clinical Results at the 11th International Conference on Retroviruses and Opportunistic Infections
12 February 2004

Share Price Movement and Disclosure
22 January 2004

Hepatitis B Preclinical Milestone
11 December 2003

Virax Review - Volume 5, Issue 2 - December 2003
2 December 2003

New Australian HIV drug Offers Hope
1 December 2003

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
11 November 2003

Annual General Meeting - Virax Holdings Limited (VHL)
5 November 2003

Annual General Meeting - Wednesday 5 November 2003, 11:00am
5 November 2003

Virax Wins International Bioterrorism Contract
20 October 2003

Virax, a member of US BioDefence Partnership Program
17 October 2003

Important Positive Result for Virax HIV Drug
16 October 2003

2003 ASIC annual Audited Accounts
30 September 2003

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
24 September 2003

Capital Raising Closes Fully Subscribed Raising $3.41 million
22 September 2003

Appendix 4e - Preliminary Final Report
12 September 2003

Pro Rata Share Issue raising exceeds $2.34 million
5 September 2003

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
3 September 2003

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
25 July 2003

Issue of Shares and Options
25 July 2003

Notice of Change of Director’s Interest
16 July 2003

Minimum Subscription Exceeded for Pro Rata Share Issue Prospectus Dated 22 May 2003
9 July 2003

Confirmation of Terms of Pro Rata Share Offer Closing 10 July 2003
3 July 20

Virax Review - Volume 5, Issue 1 - June 2003
1 July 2003

Virax Pro Rata Share Issue Extension of Closing Date to Thursday 10 July 2003 and Televideo Conference with Clearview Projects (USA)
17 June 2003

Melbourne-Based Biotech Supplies Lead HIV Vaccine Candidate for Australian HIV Vaccine Trial
5 June 2003

Fund Raising, Partnering & the Way Ahead
4 June 20

Non Renounceable Pro Rata Issue
22 May 2003

Non Renounceable Pro Rata Issue - Prospectus
22 May 2003

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
22 May 2003

Letter of Optionholders
19 May 2003

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
19 May 2003

Proposed Virax Fund Raising
13 May 2003

Resignation of Director
5 May 2003

Virax Signs Supply Agreement With Leading U.S. Biotechnology Company
1 April 2003

Appendix 3b - New issue announcement, application for quotation of additional securities and agreement
26 March 2003

New Phase For Virax Partnering Strategy
12 March 2003

Virax Announces Results of Immune Therapy Clinical Trial
17 February 2003

Virax Announces Results of Immune Therapy Clinical Trial - Questions & Answers
17 February 2003

HIV Trial Results Imminent
29 January 2003

Virax Expand Development Capability with New Vector Construction Unit
12 December 2002

Virax HIV Drug Passes Phase I Safety Review
27 November 2002

Successful Completion of the Rights Issue
23 October 2002

Virax Rights Issue Success
23 October 2002

Correction to Notice of Annual General Meeting
23 October 2002

Rights Issue Minimum Subscription Exceeded
11 October 2002

Virax Review - Volume 4, Issue 2 - September 2002
5 October 2002

Virax Share Rights Issue - Questions and Answers
5 October 2002

Virax Rights Offer in a Nutshell
5 October 2002

Virax Rights Issue
16 September 2002

Appendix 4b - Preliminary Final Report
14 September 2002

Innovative Australian HIV Drug Gets Green Light For Further Testing
3 September 2002

VIR201 Extension Study Questions and Answers
3 September 2002

Presentation by Dr Larry Ward at the Australian Partnering and Investment Forum for Emerging Biotechnology Companies, as part of AusBiotech 2002, on Tuesday, 20 August 2002

Virax To Develop Hepatitis B Treatment With New York Blood Center
19 August 2002

Virax & New York Blood Centre Hepatitis B Collaboration Questions & Answers
19 August 2002

Prostate Cancer Milestone for Virax
2 July 2002

The HIV Trial is On Track
17 June 2002

Virax Accelerates its Product Development Capability
21 May 2002

Recruitment Completed for HIV Treatment Trial
23 April 2002

Half Yearly Report and ASIC Half Yearly Accounts
8 March 2002

Extension of Share Purchase Plan - Closing Date from Tuesday, 26 February 2002 to Tuesday, 5 March 2002
20 February 2002

Virax Invited to Prestigious NY BIO Conference
18 February 2002

Virax Share Purchase Plan
31 January 2002

Past Announcements